AbbVie Inc. (ABBV)
AbbVie Statistics
Share Statistics
AbbVie has 1.77B shares outstanding. The number of shares has increased by 0.04% in one year.
Shares Outstanding | 1.77B |
Shares Change (YoY) | 0.04% |
Shares Change (QoQ) | 0.05% |
Owned by Institutions (%) | 71.91% |
Shares Floating | 1.77B |
Failed to Deliver (FTD) Shares | 257 |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 18.16M, so 1.03% of the outstanding shares have been sold short.
Short Interest | 18.16M |
Short % of Shares Out | 1.03% |
Short % of Float | 1.03% |
Short Ratio (days to cover) | 3.12 |
Valuation Ratios
The PE ratio is 73.33 and the forward PE ratio is 14.41. AbbVie's PEG ratio is -6.46.
PE Ratio | 73.33 |
Forward PE | 14.41 |
PS Ratio | 5.57 |
Forward PS | 4.7 |
PB Ratio | 94.34 |
P/FCF Ratio | 16.68 |
PEG Ratio | -6.46 |
Enterprise Valuation
AbbVie Inc. has an Enterprise Value (EV) of 320.56B.
EV / Earnings | 74.93 |
EV / Sales | 5.69 |
EV / EBITDA | 21.5 |
EV / EBIT | 35.08 |
EV / FCF | 17.05 |
Financial Position
The company has a current ratio of 0.66, with a Debt / Equity ratio of 20.19.
Current Ratio | 0.66 |
Quick Ratio | 0.55 |
Debt / Equity | 20.19 |
Total Debt / Capitalization | 95.28 |
Cash Flow / Debt | 0.28 |
Interest Coverage | 3.25 |
Financial Efficiency
Return on equity (ROE) is 1.29% and return on capital (ROIC) is 14.95%.
Return on Equity (ROE) | 1.29% |
Return on Assets (ROA) | 0.03% |
Return on Capital (ROIC) | 14.95% |
Revenue Per Employee | $1,024,254.55 |
Profits Per Employee | $77,781.82 |
Employee Count | 55,000 |
Asset Turnover | 0.42 |
Inventory Turnover | 4.04 |
Taxes
Income Tax | -570M |
Effective Tax Rate | -0.15 |
Stock Price Statistics
The stock price has increased by 12.66% in the last 52 weeks. The beta is 0.6, so AbbVie's price volatility has been higher than the market average.
Beta | 0.6 |
52-Week Price Change | 12.66% |
50-Day Moving Average | 197.14 |
200-Day Moving Average | 186.87 |
Relative Strength Index (RSI) | 49.78 |
Average Volume (20 Days) | 6.23M |
Income Statement
In the last 12 months, AbbVie had revenue of 56.33B and earned 4.28B in profits. Earnings per share was 2.42.
Revenue | 56.33B |
Gross Profit | 39.43B |
Operating Income | 9.14B |
Net Income | 4.28B |
EBITDA | 14.91B |
EBIT | 9.14B |
Earnings Per Share (EPS) | 2.42 |
Balance Sheet
The company has 5.52B in cash and 67.14B in debt, giving a net cash position of -61.62B.
Cash & Cash Equivalents | 5.52B |
Total Debt | 67.14B |
Net Cash | -61.62B |
Retained Earnings | -7.9B |
Total Assets | 135.16B |
Working Capital | -13.17B |
Cash Flow
In the last 12 months, operating cash flow was 18.81B and capital expenditures 0, giving a free cash flow of 18.81B.
Operating Cash Flow | 18.81B |
Capital Expenditures | 0 |
Free Cash Flow | 18.81B |
FCF Per Share | 10.65 |
Margins
Gross margin is 69.99%, with operating and profit margins of 16.22% and 7.59%.
Gross Margin | 69.99% |
Operating Margin | 16.22% |
Pretax Margin | 6.6% |
Profit Margin | 7.59% |
EBITDA Margin | 26.47% |
EBIT Margin | 16.22% |
FCF Margin | 33.38% |
Dividends & Yields
ABBV pays an annual dividend of $7.93, which amounts to a dividend yield of 3.16%.
Dividend Per Share | $7.93 |
Dividend Yield | 3.16% |
Dividend Growth (YoY) | 5.81% |
Payout Ratio | 330.42% |
Earnings Yield | 1.18% |
FCF Yield | 5.18% |
Analyst Forecast
The average price target for ABBV is $214.5, which is 4.6% higher than the current price. The consensus rating is "Buy".
Price Target | $214.5 |
Price Target Difference | 4.6% |
Analyst Consensus | Buy |
Analyst Count | 19 |
Scores
Altman Z-Score | 2.09 |
Piotroski F-Score | 5 |